Speciality Medicines was incorporated on February 05, 2021. The company is engaged in the marketing and distribution of specialty pharmaceutical formulations used to treat complex and chronic conditions across therapeutic areas such as oncology, immunology, neurology, and rare diseases. It offers a diverse portfolio in multiple dosage forms and operates through contract manufacturing as well as sourcing and distribution of products globally
| Bidding Dates |
|---|
| 20 Mar 2026 - 24 Mar 2026 |
| Subscription |
|---|
| 2.19x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹2,34,000 | 2 | 2 | 1000 | 2.4 M | ₹117 - ₹124 | 45.7 % | ₹274.9 M - ₹291.4 M | RHP DOC |
Speciality Medicines IPO SUBSCRIPTION STATUS
24 Mar '26Speciality Medicines IPO overall subscription rate was 2.19 times the total available shares
Speciality Medicines IPO retail subscription rate was 1.12 times in the retail segment
Speciality Medicines IPO non-institutional investor subscription rate was 6.22 times in the non-institutional investor category
Speciality Medicines IPO Qualified Institutional Bidder subscription rate was 1.72 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
24 Mar 2026 (Day 3) | 1.12x | 6.22x | 1.72x |
23 Mar 2026 (Day 2) | 0.26x | 5.62x | 0.02x |
20 Mar 2026 (Day 1) | 0.09x | 4.95x | 0.02x |
Speciality Medicines FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| 7MFY26 | 36.7 | 6.1 | 1.6 | 1.6 | 17.7% |
| FY25 | 58.3 | 8.6 | -5.8 | -6.4 | 15.6% |
| FY24 | 27.5 | 2.9 | -4.8 | -4.8 | 19.1% |
| FY23 | 23.2 | 1.7 | -3.7 | -3.7 | 15.4% |
Speciality Medicines IPO SUBSCRIPTION STATUS DETAILS
Speciality Medicines had 2.4 M shares on offer
Speciality Medicines IPO offer price was in the range ₹117 - ₹124
Speciality Medicines IPO minimum Investment was ₹234000
Speciality Medicines IPO issue size was ₹ 274.9 M - ₹ 291.4 M
Speciality Medicines had a minimum lot size of 1000 Shares per application
Speciality Medicines NUMBER OF SHARES ON OFFER
Speciality Medicines IPO IMPORTANT DATES
| Issue Open Date | 20 Mar 2026 |
| Issue close Date | 24 Mar 2026 |
| Allotment Date | 25 Mar 2026 |
| Refund Date | 27 Mar 2026 |
| Demat Account Credit Date | 27 Mar 2026 |
| Listing Date | 30 Mar 2026 |
| Listing on Exchange(s) | BSE |
| Speciality Medicines Allotment Status | Exchange/ Registrar |
Speciality Medicines IPO subscription opened on 20 Mar 2026, and closed on 24 Mar 2026
IPO allotment for Speciality Medicines was finalized on Wednesday, 25 Mar 2026
IPO listing for Speciality Medicines was on BSE on Monday, 30 Mar 2026
Speciality Medicines IPO LISTING GAINS
| Issue Price (adjusted) | 124.0 |
| Listing Open Price | 124.0 |
| Listing Close Price | 125.9 |
| Listing Gain% | 0.0% |
| Current Gain% | 26.3% |
Speciality Medicines Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Speciality Medicines Ltd. | 156.6 | 137.6 | 10.6 | 0.2 | 1.8 | 18.3 | 13.7 | 76.1 | 30 | 13 | 51.4 | 14.8 | 51.4 |
| Sun Pharmaceutical Industries Ltd. | 1945 | 466670.7 | 38.6 | 2.3 | 7.8 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 50.4 | 16.6 |
| Divi's Laboratories Ltd. | 8275 | 219675.3 | 75.1 | 2.8 | 19.6 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4924 | 187293.2 | 85.9 | 9.6 | 11.9 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 57.3 | 8.9 |
| Cipla Ltd. | 1463.8 | 118253.6 | 35.1 | -0.9 | 4.2 | 11.3 | 9.1 | 29044.6 | 2.2 | 3879.2 | -26.4 | 41.7 | -37.5 |
| Zydus Lifesciences Ltd. | 1114.2 | 112114.6 | 22.2 | 2.3 | 4.1 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 50.1 | 9.6 |
Speciality Medicines INFORMATION ON IPO ISSUE
About Speciality Medicines
Speciality Medicines was incorporated on February 05, 2021. The company is engaged in the marketing and distribution of specialty pharmaceutical formulations used to treat complex and chronic conditions across therapeutic areas such as oncology, immunology, neurology, and rare diseases. It offers a diverse portfolio in multiple dosage forms and operates through contract manufacturing as well as sourcing and distribution of products globally
Object of the Issue
- Setting up of research and development (R&D) centre at revenue city, Gujarat;
- Product registration in international markets and product development for sale in international markets
- Funding for marketing and promotional activities
- To meet working capital requirements
- General corporate purpose
Speciality Medicines - PROMOTERS
| Name |
|---|
| Parth Goyani |
| Sumit Goyani |
Speciality Medicines - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Parth Goyani | Chairman & Managing Director |
| Sumit Goyani | Whole-Time Director |
| Bhaveshkumar Ashokbhai Savani | Non-Executive Director |
| Chandresh M Unagar | Non-Executive Independent Director |
| Archana Madhav Bhayani | Non-Executive Independent Director |
Speciality Medicines Book Running Lead Manager
Unistone Capital Private Limited
mb@unistonecapital.com
Speciality Medicines Registrar to the issue
Skyline Financial Services Private Limited
ipo@skylinerta.com
Speciality Medicines Strengths
Diversified global presence
The company has a diversified geographical presence across India and multiple international markets, reducing dependence on any single region. This broad footprint supports risk mitigation and creates opportunities for sustained growth by expanding into new global markets
Diversified product portfolio
The company offers a diversified pharmaceutical portfolio across multiple therapeutic areas such as anti-infectives, cardiology, dermatology, and neurology, with a wide range of dosage forms. This balanced mix helps serve varied customer needs, reduce dependency on any single segment, and support stable and sustainable growth
Quality assurance
The company emphasizes quality as a continuous process to build and maintain strong customer relationships, supported by ISO 9001:2015 certification. It ensures high standards through accredited third-party manufacturers, timely delivery, and strict quality controls to minimize errors and product rejections
Speciality Medicines Risks
Depend on third-party vendors
The company relies on third-party suppliers for product procurement, and any disruption, delay, or price increase in supply may adversely affect its operations and financial performance. Supply availability and pricing are influenced by factors such as market fluctuations, regulatory changes, currency movements, and varying demand conditions
Quality compliance
The company must adhere to strict customer-defined quality standards and technical specifications, and any failure to comply may result in order cancellations, product recalls, or loss of customers. Such lapses could also lead to warranty claims, financial liabilities, reputational damage, and adverse impact on business performance
Capital intensive
The company’s operations are highly dependent on adequate working capital, and any shortage may disrupt day-to-day activities, delay payments, and impact order fulfilment. Insufficient liquidity or fluctuations in working capital could lead to higher financing costs, operational inefficiencies, and adverse effects on financial performance and customer relationships
IPO FAQs
The promoters of the company are Parth Goyani and Sumit Goyani.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 117.0 - 124.0.
The IPO application opens on Mar 20, 2026 and closes on Mar 24, 2026.
The minimum lot size for the IPO is 2000. The maximum lot size for the IPO is 2000.
For all category investors, the minimum application amount for this IPO is Rs. 234,000.0, the maximum value for this IPO is Rs 248,000.0.
This IPO will be allotted on Mar 25, 2026.
The refund will be credited to your account on Mar 27, 2026.
The allotted shares will be credited to your demat on Mar 27, 2026.
Speciality Medicines Ltd.’s shares listed on the stock exchanges on Mar 30, 2026.